Aungkura - Supokawej

Dr. Aungkura - Supokawej

Mahidol University, Nakhon Pathom, Thailand
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2016 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
JPJitrada Phetfong
Jitrada Phetfong
TSTanwarat Sanvoranart
Tanwarat Sanvoranart
KNKuneerat Nartprayut
Kuneerat Nartprayut
NNNatakarn Nimsanor
Natakarn Nimsanor
KSKanokwan Seenprachawong
Kanokwan Seenprachawong
ASAungkura - Supokawej
Aungkura - Supokawej
Osteoporosis, or bone loss, is a progressive, systemic skeletal disease that affects millions of people worldwide. Osteoporosis is generally age related, and it is underdiagnosed because it remains asymptomatic for several years until the development of fractures that confine daily life activities, particularly in elderly people. Most patients with osteoporotic fractures become bedridden and are in a life-threatening state. The consequences of fracture can be devastating, leading to substantial morbidity and mortality of the patients. The normal physiologic process of bone remodeling involves a balance between bone resorption and bone formation during early adulthood. In osteoporosis, this process becomes imbalanced, resulting in gradual losses of bone mass and density due to enhanced bone resorption and/or inadequate bone formation. Several growth factors underlying age-related osteoporosis and their signaling pathways have been identified, such as osteoprotegerin (OPG)/receptor activator of nuclear factor B (RANK)/RANK ligand (RANKL), bone morphogenetic protein (BMP), wingless-type MMTV integration site family (Wnt) proteins and signaling through parathyroid hormone receptors. In addition, the pathogenesis of osteoporosis has been connected to genetics. The current treatment of osteoporosis predominantly consists of antiresorptive and anabolic agents; however, the serious adverse effects of using these drugs are of concern. Cell-based replacement therapy via the use of mesenchymal stem cells (MSCs) may become one of the strategies for osteoporosis treatment in the future.

15 February 2017 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
VPVeda Prachayasittikul
Veda Prachayasittikul
PPPhilip Prathipati
Philip Prathipati
RPReny Pratiwi
Reny Pratiwi
CPChuleeporn Phanus-Umporn
Chuleeporn Phanus-Umporn
AMAijaz Ahmad Malik
Aijaz Ahmad Malik
CNChanin Nantasenamat
Chanin Nantasenamat
Introduction: Epigenetic modification has been implicated in a wide range of diseases and the ability to modulate such systems is a lucrative therapeutic strategy in drug discovery. Areas covered: This article focuses on the concepts and drug discovery aspects of epigenomics. This is achieved by providing a survey of the following concepts: (i) factors influencing epigenetics, (ii) diseases arising from epigenetics, (iii) epigenetic enzymes as druggable targets along with coverage of existing FDA-approved drugs and pharmacological agents, and (iv) drug repurposing/repositioning as a means for rapid discovery of pharmacological agents targeting epigenetics. Expert opinion: Despite significant interests in targeting epigenetic modifiers as a therapeutic route, certain classes of target proteins are heavily studied while some are less characterized. Thus, such orphan target proteins are not yet druggable with limited report of active modulators. Current research points towards a great future with novel drugs directed to the many complex multifactorial diseases of humans, which are still often poorly understood and difficult to treat.

23 November 2012 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
SMS. Manochantr
S. Manochantr
YUY. U‐Pratya
Y. U‐Pratya
PKP. Kheolamai
P. Kheolamai
SRS. Rojphisan
S. Rojphisan
MCM. Chayosumrit
M. Chayosumrit
SIS. Issaragrisil
S. Issaragrisil

19 February 2016 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
JPJitrada Phetfong
Jitrada Phetfong
ASAungkura - Supokawej
Aungkura - Supokawej
MWMethichit Wattanapanitch
Methichit Wattanapanitch
PKPakpoom Kheolamai
Pakpoom Kheolamai
YUYaowalak U-Pratya
Yaowalak U-Pratya
SISurapol Issaragrisil
Surapol Issaragrisil

14 November 2018 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
KSKanokwan Seenprachawong
Kanokwan Seenprachawong
TTTulyapruek Tawornsawutruk
Tulyapruek Tawornsawutruk
CNChanin Nantasenamat
Chanin Nantasenamat
PNPornlada Nuchnoi
Pornlada Nuchnoi
SHSuradej Hongeng
Suradej Hongeng
ASAungkura - Supokawej
Aungkura - Supokawej
Mesenchymal stem cell (MSC) is a type of stem cell that is capable of differentiating into osteoblasts and adipocytes. The pathological perturbation of MSC fate determination is well demonstrated by the replacement of bone tissues with fat in those with osteoporosis and osteopenia. Cell fate determination can be regulated by epigenetic and post-transcriptional mechanisms. MicroRNAs (miRNAs) are small endogenous non-coding RNA molecules that mediates the post-transcriptional regulation of genes expression. We hypothesized that miRNA specified to PPARγ, a major transcription factor of adipogenesis, is responsible for the differentiation of MSCs into osteoblasts. Candidate miRNA that is responsible for target gene inhibition was identified from the miRNA database via bioinformatic analyses. In this study, miR-130a and miR-27b were selected for investigation on their role in specifically binding to peroxisome proliferator-activated receptor γ (PPARγ) via in vitro osteogenesis of human MSCs. During osteogenic differentiation of human MSCs, the expression level of miR-130a and miR-27b were found to be upregulated. In the meanwhile, adipogenic marker genes (PPARγ and C/EBPβ) were found to decrease, which is in contrary to the increased expression of osteogenic marker genes (RUNX2 and Osterix). MSCs were transfected with mimics and inhibitors of miR-130a and miR-27b during in vitro osteogenesis followed by evaluation for the presence of osteogenic markers via quantitative gene expression, Western blot analysis and alkaline phosphatase activity assay. The overexpression of miR-130a and miR-27b is shown to enhance osteogenesis by increasing the gene expression of RUNX2 and Osterix, the protein expression of RUNX2, COL1A1, and Osterix as well as the alkaline phosphatase activity. Taken altogether, these results suggested that miR-130a and miR-27b could promote osteogenesis in human MSCs by targeting the PPARγ.

14 December 2021 in FEBS Open Bio
Verified
Journal Article
Open access
PDF file
JPJitrada Phetfong
Jitrada Phetfong
TTTulyapruek Tawonsawatruk
Tulyapruek Tawonsawatruk
WKWitchayapon Kamprom
Witchayapon Kamprom
POPawared Ontong
Pawared Ontong
DTDalina Tanyong
Dalina Tanyong
ASAungkura - Supokawej
Aungkura - Supokawej
Mesenchymal stem cells (MSCs) have been proposed to have potential for tissue engineering and cell therapy due to their multilineage differentiation potential and ability to secrete numerous paracrine factors, including extracellular vesicles (EVs). Increasing evidence has demonstrated that MSC‐derived EVs (MSC‐EVs) are able to induce the repair of tissue damage and regulate the immune system. However, their role in cancer development is still unclear. Reports have suggested that whether MSC‐EVs have an inhibitory or promoting effect on cancer is dependent on the type of cancer. In this study, the role of MSC‐EVs in the regulation of leukemic cell growth in vitro was investigated. The EVs were collected from conditioned media of MSCs by ultrafiltration using a 10 kDa molecular weight cutoff (MWCO) filter. The isolated MSC‐EVs were comprised of microvesicles and exosomes, as examined by the size of vesicles and exosomal proteins, CD81 and flotillin‐1. Cell proliferation, cell cycle status, apoptosis, and gene expression were examined in the leukemic cell lines NB4 and K562 after treatment with MSC‐EVs. Suppression of cell proliferation and induction of apoptosis was observed. Gene expression analysis revealed differential expression of apoptotic‐related genes in NB4 and K562. MSC‐EVs increased the expression of BID and BAX and decreased expression of BCL2, indicating the induction of intrinsic apoptosis in NB4. In contrast, MSC‐EVs increased the expression of the death receptor gene TRAILR2 and cell cycle regulator genes P21 and CCNE2 in K562. In conclusion, MSC‐EVs partially induce leukemic cell apoptosis, and thus may have potential for the development of supportive therapies for leukemia.